Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 12874415.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors performed an open, randomized trial in patients with inclusion body myositis comparing 1) 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group) with 2) 12-month MTX treatment preceded by 7 days of IV anti-T-lymphocyte immunoglobulin treatment (ATG group). Eleven patients were randomized; 10 patients completed 12 months follow-up. Myometry showed that patients in the ATG group (n = 6) increased in mean muscle strength by 1.4% compared with the MTX group (n = 5), whose muscle strength decreased by 11.1% (p = 0.021).
Medical subject headings
- Antilymphocyte Serum
- Autoimmune Diseases
- Immunosuppressive Agents
- Myositis, Inclusion Body
- T-Lymphocytes